- MGC Pharmaceuticals (MXC) has received a significantly increased order from Swiss PharmaCan (SPC) for its ArtemiC Rescue product line
- The companies first entered an agreement last month with Swiss PharmaCan initially receiving 40,000 units per quarter over a three year period
- MGC Pharma today announced an 85 per cent increase to the initial purchase order, bringing the new total order to more than $425,000
- ArtemiC is MGC’s natural, immune-modulation formula that is made up of Vitamin C and herbal extracts used to treat anti-inflammatory illnesses
- A phase II trial from December showed that the product reduces the symptoms and pain associated with COVID-19
- MGC Pharma is up 2.5 per cent, trading at 8.2 cents
MGC Pharmaceuticals (MXC) has received a significantly increased order from Swiss PharmaCan (SPC) for its ArtemiC Rescue product line.
The companies first entered an agreement last month with Swiss PharmaCan initially receiving 40,000 units per quarter over a three-year period.
It will then be distributed as a food supplement worldwide with the exception of a few select countries.
SPC will be responsible for the acquisition of relevant permits, approvals, licences and certificates, as well as marketing, promotion, advertising and import.
MGC Pharma today announced an 85 per cent increase to the initial purchase order received in February, bringing the new initial total order to more than $425,000.
ArtemiC is made up of Artemisinin, a drug from a fern-like plant that is used against malaria, and Curcumin, a chemical that aids in anti-inflammatory and antioxidants.
It is then mixed with Vitamin C and Boswellia serrata, a herbal extract used to treat inflammatory illnesses.
Following a phase two double-blind, placebo-controlled clinical trial on COVID-19 patients, ArtemiC was shown to reduce the symptoms and pain associated with COVID-19.
Further, the product was shown to be safe and effective for human use.
“We are pleased to have extended our agreement with Swiss PharmaCan AG for ArtemiC Rescue,” Co-Founder and Managing Director Roby Zomer said.
“This further agreement will provide more people access to the natural therapeutic benefits of the supplement and ease suffering following the successful phase two trial results in December,” he added.
MGC Pharma is up 2.5 per cent on the market, trading at 8.2 cents at 11:27 am AEDT.